Bluejay Diagnostics reports 2022 net loss $9.3M; FDA submission delayed to H1 2024

Bluejay Diagnostics, Inc.

Net loss $9.3M ($0.46 per share) vs $3.5M ($0.41 per share) in 2021.
Cash and cash equivalents $10.1M, down from $19.0M year-over-year.
R&D expense increased 262% to support clinical trials for planned FDA submission.
FDA feedback requires expanded clinical study; de novo submission timeline pushed to H1 2024.
Company to require additional funding to reach commercialization due to delay.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bluejay Diagnostics, Inc. reported the year ended December 31, 2022 results: net income $9.3 million, or $0.46 per share, EPS $0.46 per share.

Period: the year ended December 31, 2022
Net income: $9.3 million, or $0.46 per share
EPS: $0.46 per share
Result: reported results

Exact text from the filing

Bluejay Diagnostics Reports 2022 Financial Results

View on SEC.gov

Browse all earnings releases →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-021408

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.